Aims
DWP16001 is a novel sodium-glucose cotransporter-2 (SGLT2) inhibitor
under development for the treatment of type 2 diabetes mellitus. This
study was conducted to evaluate the pharmacokinetics (PK),
pharmacodynamics (PD), and safety of DWP16001 after single and multiple
doses in healthy subjects.